中国药业2025，Vol.34Issue(4)：111-114,4.DOI:10.3969/j.issn.1006-4931.2025.04.027
薄芝糖肽联合五痹胶囊佐治局限性硬皮病临床观察
Clinical Observation of Bozhi Glycopeptide Combined with Wubi Capsules in the Adjuvant Treatment of Localized Scleroderma
摘要
Abstract
Objective To investigate the clinical efficacy of Bozhi glycopeptide combined with Wubi Capsules in the adjuvant treatment of localized scleroderma,and its effect on the soluble interleukin-2 receptor(sIL-2R),thymus and activation-regulated chemokine(TRAC)and fibroblast growth factor(FGF)levels in patients.Methods Sixty patients with localized scleroderma admitted to the hospital from June 2021 to June 2023 were selected and randomly divided into the observation group and the control group by a random number table method,with 30 cases in each group.Both groups received phototherapy,on this basis,the patients in the observation group received intravenous drip of Bozhi Glycopeptide Injection and oral Wubi Capsules.All patients were treated for three courses with one month as a course.Results The total effective rate in the observation group was 96.67%,which was significantly higher than 73.33%in the control group(P<0.05).After treatment,the scores of traditional Chinese medicine(TCM)syndromes(including skin hardness,swelling,tingling,itching,tongue redness,pulse string)and skin hardness in the observation group were significantly lower than those in the control group(P<0.05);the sIL-2R,TRAC and FGF levels were significantly lower than those in the control group(P<0.05);the complement C3,complement C4 and CD40 cell levels were significantly lower than those in the control group,while the natural killer cell levels were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions was comparable between the observation group and the control group(16.67%vs.13.33%,P>0.05).Conclusion The adjuvant treatment of Bozhi glycopeptide combined with Wubi Capsules can alleviate the TCM syndromes of patients with localized scleroderma,decrease the skin hardness score,inhibit the expression of sIL-2R,TRAC,FGF,and improve immune function.关键词
局限性硬皮病/薄芝糖肽注射液/五痹胶囊/可溶性白细胞介素 2 受体/胸腺和调控活化的趋化因子/成纤维细胞生长因子Key words
localized scleroderma/Bozhi Glycopeptide Injection/Wubi Capsules/sIL-2R/TRAC/FGF分类
医药卫生引用本文复制引用
谷文佳,王春艳,熊建军,李晨,宋真真,李晓云..薄芝糖肽联合五痹胶囊佐治局限性硬皮病临床观察[J].中国药业,2025,34(4):111-114,4.基金项目
河北省中医药管理局中医药类科研指令性计划课题[2021233]. （）
